The Congressional Budget Office found that even the most effective drug pricing proposals might only reduce costs by 5%, prompting calls for comprehensive strategies.
Consumer rights advocates argue that simply enacting one policy will not suffice to control outrageously high US drug prices; multiple strategies must be employed.
The report reveals that the U.S. paid 2.7 times more for drugs in 2022 than other OECD nations, highlighting the urgent need for systemic reform.
The exorbitant costs of new medications, like Wegovy and Ozempic, have sparked concern among policymakers as they threaten to overwhelm the healthcare system.
Collection
[
|
...
]